Schrödinger Q3 2026 net loss widens 15% to $37.71 million
Bitget2026/11/04 21:14- Schrödinger’s third-quarter 2026 net loss widened 15% year over year to $37.71 million.
- Total revenue rose 19% to $64.5 million, while drug discovery revenue jumped 86% to $24.19 million, primarily due to a Structure Therapeutics milestone.
- Annual contract value climbed 17% to $44.7 million, while hosted software revenue increased 49% to $17.2 million.
- In September, the company licensed two early-stage programs to co-founded Tectora Therapeutics for equity and eligibility for milestones and royalties.
- Full-year 2026 guidance increased to $222 million–$232 million for annual contract value and $75 million–$85 million for drug discovery revenue.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Rumor: Tesla (TSLA.US) and SpaceX (SPCX.US) plan Terafab monthly production of one million wafers, feasibility questioned
According to reports, Tesla (TSLA.US) and SpaceX (SPCX.US) plan to achieve a production capacity of 1 million semiconductor wafers per month at the proposed Terafab factory starting in 2032.
Eurozone Sentix Investor Confidence Index slips to 2.4 in November from 2.7 in October
SoftBank develops contingency plans for slowdown in US data center business, considers shifting to other countries
A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.
Crypto prices
More
